Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Kody A Waldstein"'
Autor:
Kody A Waldstein, Steven M Varga
Publikováno v:
PLoS Pathogens, Vol 18, Iss 12, p e1011014 (2022)
Externí odkaz:
https://doaj.org/article/3422b9fd4d0a4ddfb51cd5aa8f490b68
Publikováno v:
Journal of Clinical and Translational Science, Vol 7, Pp 143-144 (2023)
OBJECTIVES/GOALS: Viral acute rhinosinusitis (ARS), a.k.a, the common cold, affects millions every year. The symptoms caused by viral ARS dramatically affect the general well-being and functional levels of patients, causing work and school absence, a
Externí odkaz:
https://doaj.org/article/3a3c4ca0a1e848129a8140c2d1a7398c
Autor:
Kody A Waldstein, Jirong Yi, Myung Cho, Raghu Mudumbai, Xiaodong Wu, Steven M Varga, Weiyu Xu
Publikováno v:
PLoS Computational Biology, Vol 18, Iss 10, p e1010629 (2022)
The rapid spread of SARS-CoV-2 has placed a significant burden on public health systems to provide swift and accurate diagnostic testing highlighting the critical need for innovative testing approaches for future pandemics. In this study, we present
Externí odkaz:
https://doaj.org/article/e62052c9359544c19a1ebbe6392dec31
Autor:
Jorge A. Soto, Laura M. Stephens, Kody A. Waldstein, Gisela Canedo-Marroquín, Steven M. Varga, Alexis M. Kalergis
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Externí odkaz:
https://doaj.org/article/ef14addc9e324fc9ad2b045498e073b9
Publikováno v:
The LaryngoscopeBIBLIOGRAPHY.
Viral acute rhinosinusitis (ARS) is the leading cause of work and school absence and antibiotic over-prescription. There are limited treatment options available to ameliorate the symptoms caused by viral ARS. We have previously demonstrated that topi
Autor:
Kevin L. Legge, Kathleen A. Ross, Kody A Waldstein, Steven M. Varga, Laura M Stephens, Balaji Narasimhan, Jason S. McLellan
Publikováno v:
J Immunol
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in both young children and in older adults. Despite the morbidity, mortality, and high economic burden caused by RSV worldwide, no licensed vaccine is currently
Autor:
Natalie I Mazur, Jonne Terstappen, Ranju Baral, Azucena Bardají, Philippe Beutels, Ursula J Buchholz, Cheryl Cohen, James E Crowe, Clare L Cutland, Linda Eckert, Daniel Feikin, Tiffany Fitzpatrick, Youyi Fong, Barney S Graham, Terho Heikkinen, Deborah Higgins, Siddhivinayak Hirve, Keith P Klugman, Leyla Kragten-Tabatabaie, Philippe Lemey, Romina Libster, Yvette Löwensteyn, Asuncion Mejias, Flor M Munoz, Patrick K Munywoki, Lawrence Mwananyanda, Harish Nair, Marta C Nunes, Octavio Ramilo, Peter Richmond, Tracy J Ruckwardt, Charles Sande, Padmini Srikantiah, Naveen Thacker, Kody A Waldstein, Dan Weinberger, Joanne Wildenbeest, Dexter Wiseman, Heather J Zar, Maria Zambon, Louis Bont
Publikováno v:
The lancet infectious diseases
Mazur, N I, Terstappen, J, Baral, R, Bardají, A, Beutels, P, Buchholz, U J, Cohen, C, Crowe, J E, Cutland, C L, Eckert, L, Feikin, D, Fitzpatrick, T, Fong, Y, Graham, B S, Heikkinen, T, Higgins, D, Hirve, S, Klugman, K P, Kragten-tabatabaie, L, Lemey, P, Libster, R, Löwensteyn, Y, Mejias, A, Munoz, F M, Munywoki, P K, Mwananyanda, L, Nair, H, Nunes, M C, Ramilo, O, Richmond, P, Ruckwardt, T J, Sande, C, Srikantiah, P, Thacker, N, Waldstein, K A, Weinberger, D, Wildenbeest, J, Wiseman, D, Zar, H J, Zambon, M & Bont, L 2022, ' Respiratory syncytial virus prevention within reach : the vaccine and monoclonal antibody landscape ', The Lancet Infectious Diseases, vol. 23, no. 1, pp. e2-e21 . https://doi.org/10.1016/S1473-3099(22)00291-2
Mazur, N I, Terstappen, J, Baral, R, Bardají, A, Beutels, P, Buchholz, U J, Cohen, C, Crowe, J E, Cutland, C L, Eckert, L, Feikin, D, Fitzpatrick, T, Fong, Y, Graham, B S, Heikkinen, T, Higgins, D, Hirve, S, Klugman, K P, Kragten-tabatabaie, L, Lemey, P, Libster, R, Löwensteyn, Y, Mejias, A, Munoz, F M, Munywoki, P K, Mwananyanda, L, Nair, H, Nunes, M C, Ramilo, O, Richmond, P, Ruckwardt, T J, Sande, C, Srikantiah, P, Thacker, N, Waldstein, K A, Weinberger, D, Wildenbeest, J, Wiseman, D, Zar, H J, Zambon, M & Bont, L 2022, ' Respiratory syncytial virus prevention within reach : the vaccine and monoclonal antibody landscape ', The Lancet Infectious Diseases, vol. 23, no. 1, pp. e2-e21 . https://doi.org/10.1016/S1473-3099(22)00291-2
Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory syncytial virus vaccine or immunoprophylaxis remain highly
Autor:
Michael Myung Cho, Jirong Yi, Steven M. Varga, Raghuraman Mudumbai, Xiaodong Wu, Weiyu Xu, Kody A Waldstein
Publikováno v:
medRxiv
article-version (status) pre
article-version (number) 1
article-version (status) pre
article-version (number) 1
The rapid spread of SARS-CoV-2 has placed a significant burden on public health systems to provide rapid and accurate diagnostic testing highlighting the critical need for innovative testing approaches for future pandemics. In this study, we present
Autor:
Waldstein, Kody A.1 (AUTHOR), Varga, Steven M.1,2,3 (AUTHOR) steven-varga@uiowa.edu
Publikováno v:
PLoS Pathogens. 12/29/2022, Vol. 18 Issue 12, p1-9. 9p.
Autor:
Waldstein, Kody A.1 (AUTHOR), Yi, Jirong2 (AUTHOR), Cho, Myung3 (AUTHOR), Mudumbai, Raghu2 (AUTHOR), Wu, Xiaodong2 (AUTHOR), Varga, Steven M.1,4,5 (AUTHOR), Xu, Weiyu2 (AUTHOR) weiyu-xu@uiowa.edu
Publikováno v:
PLoS Computational Biology. 10/24/2022, Vol. 18 Issue 10, p1-20. 20p. 3 Diagrams, 4 Charts.